by Roger Longman
Gilead’s near-acquisition, in the midst of the financing drought, highlights the key issue of management exhaustion in an industry where...
Gilead's Metamorphoses
Founded to pursue antisense, Gilead recognized that antisense was too long-term to support the continual financings they knew would be necessary to create a self-sustaining drug business. Thus Gilead began a series of transformations, eventually crafting an image for itself as a near-term antiviral company. Sidebar: Isis Stays Pure: As Gilead has shape-shifted into an antiviral player, Isis has continued to carry the antisense torch. And, says Stanley Crooke, MD, PhD, the company's CEO, Isis' develop
More from Business Strategy
More from In Vivo
• By
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
• By
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
• By
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.